Two Sigma Advisers LP Sells 252,800 Shares of Moderna, Inc. (NASDAQ:MRNA)

Two Sigma Advisers LP reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 70.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 103,700 shares of the company's stock after selling 252,800 shares during the period. Two Sigma Advisers LP's holdings in Moderna were worth $4,312,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP boosted its holdings in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after acquiring an additional 281 shares during the last quarter. Howard Capital Management Inc. boosted its holdings in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after acquiring an additional 297 shares during the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after acquiring an additional 345 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of several analyst reports. UBS Group reduced their target price on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Morgan Stanley reduced their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Royal Bank of Canada dropped their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $53.58.

Moderna Price Performance

Shares of MRNA traded down $0.65 during midday trading on Friday, hitting $26.29. 4,455,528 shares of the company traded hands, compared to its average volume of 8,046,878. The stock has a 50-day moving average of $26.70 and a 200-day moving average of $34.14. Moderna, Inc. has a one year low of $23.15 and a one year high of $158.82. The firm has a market cap of $10.17 billion, a P/E ratio of -2.83 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. During the same period in the prior year, the business posted ($3.07) earnings per share. The company's revenue was down 35.3% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.